18399827

Source:http://linkedlifedata.com/resource/pubmed/id/18399827

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0019932, umls-concept:C0026088, umls-concept:C0031809, umls-concept:C0282460, umls-concept:C0376358, umls-concept:C0701303, umls-concept:C1511524, umls-concept:C1707520
pubmed:issue	9
pubmed:dateCreated	2008-4-10
pubmed:abstractText	To evaluate mifepristone (RU-486) in patients with castration-resistant prostate cancer (CRPC), with a correlative assessment of serum androgens and androgen metabolites
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/100886721
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Androgens, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Hormonal, http://linkedlifedata.com/resource/pubmed/chemical/Hormone Antagonists, http://linkedlifedata.com/resource/pubmed/chemical/Mifepristone, http://linkedlifedata.com/resource/pubmed/chemical/Prostate-Specific Antigen, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Androgen
pubmed:status	MEDLINE
pubmed:month	May
pubmed:issn	1464-410X
pubmed:author	pubmed-author:BalkSteven PSP, pubmed-author:BarbDianaD, pubmed-author:BubleyGlenn JGJ, pubmed-author:GelmannEdward PEP, pubmed-author:KantoffPhilip WPW, pubmed-author:ManolaJudithJ, pubmed-author:MantzorosChristosC, pubmed-author:OhWilliam KWK, pubmed-author:SmithMatthewM, pubmed-author:TaplinMary-EllenME
pubmed:issnType	Electronic
pubmed:volume	101
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1084-9
pubmed:meshHeading	pubmed-meshheading:18399827-Aged, pubmed-meshheading:18399827-Aged, 80 and over, pubmed-meshheading:18399827-Androgens, pubmed-meshheading:18399827-Antineoplastic Agents, Hormonal, pubmed-meshheading:18399827-Castration, pubmed-meshheading:18399827-Cell Communication, pubmed-meshheading:18399827-Disease Progression, pubmed-meshheading:18399827-Hormone Antagonists, pubmed-meshheading:18399827-Humans, pubmed-meshheading:18399827-Male, pubmed-meshheading:18399827-Middle Aged, pubmed-meshheading:18399827-Mifepristone, pubmed-meshheading:18399827-Neoplasm Metastasis, pubmed-meshheading:18399827-Neoplasms, Hormone-Dependent, pubmed-meshheading:18399827-Prostate-Specific Antigen, pubmed-meshheading:18399827-Prostatic Neoplasms, pubmed-meshheading:18399827-Receptors, Androgen, pubmed-meshheading:18399827-Treatment Outcome
pubmed:year	2008
pubmed:articleTitle	A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.
pubmed:affiliation	Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA. mtaplin@partners.org
pubmed:publicationType	Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase II